← All companies

Revolution Medicines

Healthcare & Life Sci

Company overview

Revolution Medicines is a biopharmaceutical company. It develops targeted medicines for cancers driven by RAS gene mutations, known as RAS-addicted cancers. Its pipeline includes RAS(ON) inhibitor drugs called daraxonrasib, elironrasib and zoldonrasib, which are in clinical trials.

The FDA approved daraxonrasib in August 2026. It is the first RAS-targeted therapy approved for metastatic pancreatic cancer, marking a step from the pipeline to an approved medicine for patients. Revolution Medicines is an H-1B sponsor.

Industry
Healthcare & Life Sci
Headquarters
Redwood City, United States

Filters

Create your account

Create an account to save jobs and track applications.